Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes

Ketaki Panse; Abraham Hang; Jonathan Ruiz; Sapna Gangaputra; Sili Fan; Jeffrey Fine; Parisa Emami-Naeini; Glenn Yiu; Kareem Moussa

doi:10.1016/j.ajo.2024.11.022

Suprachoroidal Triamcinolone Acetonide for Noninfectious Uveitis: Real-World Impact on Clinical Outcomes

Am J Ophthalmol. 2024 Dec 5:271:259-267. doi: 10.1016/j.ajo.2024.11.022. Online ahead of print.

Authors

Ketaki Panse¹, Abraham Hang¹, Jonathan Ruiz², Sapna Gangaputra³, Sili Fan⁴, Jeffrey Fine⁴, Parisa Emami-Naeini¹, Glenn Yiu¹, Kareem Moussa⁵

Affiliations

¹ From the Department of Ophthalmology & Vision Science, University of California (K.P., A.H., P.E.-N., G.Y., K.M.), Davis, Sacramento, California, USA.
² School of Medicine, University of California (J.R.), Davis, Sacramento, California, USA.
³ Vanderbilt Eye Institute, Vanderbilt University Medical Center (S.G.), Nashville, Tennessee, USA.
⁴ Division of Biostatistics, University of California (S.F., J.F.), Davis, Sacramento, California, USA.
⁵ From the Department of Ophthalmology & Vision Science, University of California (K.P., A.H., P.E.-N., G.Y., K.M.), Davis, Sacramento, California, USA. Electronic address: kamoussa@ucdavis.edu.

PMID: 39645179
DOI: 10.1016/j.ajo.2024.11.022

Abstract

Purpose: To evaluate clinically relevant outcomes following suprachoroidal triamcinolone acetonide (TA) injection in eyes with noninfectious uveitis.

Design: Retrospective interventional case series.

Methods: Sixty-one eyes (51 patients) who underwent suprachoroidal TA injection between January 1, 2022 and July 1, 2024 were included from a single institution. Main outcome measures included change in central subfield thickness (CST) and best-corrected visual acuity (BCVA) at 6, 12, and 24 weeks in eyes with macular edema and improvement in fluorescein angiography (FA) score at 6 weeks in eyes who underwent FA.

Results: Fifty-two eyes underwent suprachoroidal TA injection for uveitic macular edema. Mean CST improved from 437.61 microns at time of injection to 348.17 microns 6 weeks after (mean difference 89.44 microns, p < 0.0001, n = 47). Additional treatment for macular edema was required for 17% (8/48 eyes), 48% (14/29 eyes), and 41% (9/22 eyes) of eyes that returned for follow-up at 6, 12, and 24 weeks, respectively. Of the 17 eyes that returned for follow-up at all visits (6, 12, and 24 weeks), 41.2% (7/17 eyes) did not require any additional treatment during the 24-week follow-up period. Ten eyes underwent FA at time of injection and 6 weeks later. The mean FA score improved from 11.74 to 9.14 (mean difference 2.60, p = 0.047). No serious adverse events occurred.

Conclusions: Suprachoroidal TA resulted in significant improvement in outcome measures, including central subfield thickness in eyes with macular edema, and leakage on fluorescein angiography, with a favorable side effect profile in real-world clinical practice.